PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- Drug: Combination of PTT-936 and anti-PD-1/L1 therapy
- First Posted Date
- 2024-02-06
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Pyrotech Therapeutics, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT06244992
- Locations
- 🇺🇸
Precision NextGen Oncology and Research Center, Beverly Hills, California, United States
🇺🇸D&H Cancer Research Center, Margate, Florida, United States
🇺🇸The START Center, San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath